Pit- and trench-forming osteoclasts: a distinction that matters

Abstract

Osteoclasts (OCs) seeded on bone slices either drill round pits or dig long trenches. Whereas pits correspond to intermittent resorption, trenches correspond to continuous and faster resorption and require a distinct assembly of the resorption apparatus. It is unknown whether the distinction between pits and trenches has any biological relevance. Using OCs prepared from different blood donors, we found that female OCs achieved increased resorption mainly through pit formation, whereas male OCs did so through trench formation. Trench formation went along with high collagenolytic activity and high cathepsin K (CatK) expression, thereby allowing deeper demineralization. A specific CatK inhibitor abrogated the generation of trenches, while still allowing the generation of pits. OCs obtained from bone marrow were more prone to generate trenches than those obtained from blood. Scanning electron microscopy of bone surfaces eroded in vivo showed trenches and pits of similar size as those made by OCs in culture. We conclude that the distinction between trench- and pit-forming OCs is relevant to the differences among OCs from different skeletal sites, different individuals, including gender, and results from differences in collagenolytic power. This indicates a biological relevance and highlights the importance of discriminating between pits and trenches when assessing resorption.

Bone resorption: Digging further into bone degradation

Danish researchers have shown that the mechanism used by bone-degrading cells (osteoclasts) is determined by their source. Bone degradation by osteoclasts helps growth and repair but, in excess, can cause bone disease. Osteoclasts dig either circular pits or long trenches into bone. Trenches cause faster degradation, but the full significance of the two mechanisms is unknown. Kent Søe and Jean-Marie Delaissé, from the University of Southern Denmark and colleagues examined degradation by osteoclasts from different sources. Osteoclasts generated from bone marrow dug a greater proportion of trenches than osteoclasts generated from blood. Osteoclasts from men dug more trenches than pits, whereas the opposite was true of osteoclasts from women. Inhibiting the enzyme cathepsin K reversed the bias for trenches that was seen with osteoclasts from bone marrow and men, and could lead to a therapy for bone disease.

References

[1] Delaissé JM, Andersen TL, Engsig MT, Henriksen K, Troen T, Blavier L. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech, 2003, 61: 504-513

[2] Saftig P, Hunziker E, Wehmeyer O et al Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A, 1998, 95: 13453-13458

[3] Takahashi N, Ejiri S, Yanagisawa S, Ozawa H. Regulation of osteoclast polarization. Odontology, 2007, 95: 1-9

[4] Søe K, Merrild DM, Delaissé JM. Steering the osteoclast through the demineralization-collagenolysis balance. Bone, 2013, 56: 191-198

[5] Lakkakorpi PT, Väänänen HK. Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro.. J Bone Miner Res, 1991, 6: 817-826

[6] Saltel F, Destaing O, Bard F, Eichert D, Jurdic P. Apatite-mediated actin dynamics in resorbing osteoclasts. Mol Biol Cell, 2004, 15: 5231-5241

[7] Hirvonen MJ, Fagerlund K, Lakkakorpi P, Väänänen HK, Mulari MT. Novel perspectives on the transcytotic route in osteoclasts. Bonekey Rep, 2013, 2: 306

[8] Mulari MT, Zhao H, Lakkakorpi PT, Väänänen HK. Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic, 2003, 4: 113-125

[9] Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen HK. Removal of osteoclast bone resorption products by transcytosis. Science, 1997, 276: 270-273

[10] Stenbeck G, Horton MA. A new specialized cell-matrix interaction in actively resorbing osteoclasts. J Cell Sci, 2000, 113: 1577-1587

[11] Rumpler M, Würger T, Roschger P et al Osteoclasts on bone and dentin in vitro: mechanism of trail formation and comparison of resorption behavior. Calcif Tissue Int, 2013, 93: 526-539

[12] Vanderoost J, Søe K, Merrild DM, Delaissé JM, van Lenthe GH. Glucocorticoid-induced changes in the geometry of osteoclast resorption cavities affect trabecular bone stiffness. Calcif Tissue Int, 2013, 92: 240-250

[13] Everts V, Korper W, Jansen DC et al Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J, 1999, 13: 1219-1230

[14] Everts V, Korper W, Hoeben KA et al Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res, 2006, 21: 1399-1408

[15] Gowen M, Lazner F, Dodds R et al Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res, 1999, 14: 1654-1663

[16] Garnero P, Ferreras M, Karsdal MA et al The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res, 2003, 18: 859-867

[17] Everts V, Delaissé JM, Korper W, Niehof A, Vaes G, Beertsen W. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol, 1992, 150: 221-231

[18] Everts V, Delaissé JM, Korper W, Beertsen W. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res, 1998, 13: 1420-1430

[19] Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaissé JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res, 2005, 65: 9943-9952

[20] Søe K, Delaissé JM. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J Bone Miner Res, 2010, 25: 2184-2192

[21] Gallagher JA. Human osteoblast culture. Methods Mol Med, 2003, 80: 3-18

[22] Foged NT, Delaissé JM, Hou P et al Quantification of the collagenolytic activity of isolated osteoclasts by enzyme-linked immunosorbent assay. J Bone Miner Res, 1996, 11: 226-237

[23] Lund T, Søe K, Abildgaard N et al First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol, 2010, 85: 290-299

[24] Andreasen CM, Ding M, Overgaard S, Bollen P, Andersen TL. A reversal phase arrest uncoupling the bone formation and resorption contributes to the bone loss in glucocorticoid treated ovariectomised aged sheep. Bone, 2015, 75: 32-39

[25] Gentzsch C, Delling G, Kaiser E. Microstructural classification of resorption lacunae and perforations in human proximal femora. Calcif Tissue Int, 2003, 72: 698-709

[26] Mulari MT, Qu Q, Härkönen PL, Väänänen HK. Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro. Calcif Tissue Int, 2004, 75: 253-261

[27] Jones SJ, Boyde A, Ali NN, Maconnachie E. A review of bone cell and substratum interactions - an illustration of the role of scanning electron-microscopy. Scanning, 1985, 7: 5-24

[28] Zhuo Y, Gauthier JY, Black WC, Percival MD, Duong LT. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Bone, 2014, 67: 269-280

[29] Drake FH, Dodds RA, James IE et al Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem, 1996, 271: 12511-12516

[30] Tezuka K, Tezuka Y, Maejima A et al Molecular cloning of a possible cysteine proteinase predominantly expressed in osteoclasts. J Biol Chem, 1994, 269: 1106-1109

[31] Garnero P, Borel O, Byrjalsen I et al The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem, 1998, 273: 32347-32352

[32] Delaisse JM, Boyde A, Maconnachie E et al The effects of inhibitors of cysteine-proteinases and collagenase on the resorptive activity of isolated osteoclasts. Bone, 1987, 8: 305-313

[33] Inui T, Ishibashi O, Inaoka T et al Antisense oligodeoxynucleotide inhibits osteoclastic bone resorption. J Biol Chem, 1997, 272: 8109-8112

[34] Parikka V, Lehenkari P, Sassi ML et al Estrogen reduces the depth of resorption pits by disturbing the organic bone matrix degradation activity of mature osteoclasts. Endocrinology, 2001, 142: 5371-5378

[35] Susa M, Luong-Nguyen NH, Cappellen D, Zamurovic N, Gamse R. Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med, 2004, 2: 6

[36] Boyde A, Maconnachie E, Reid SA, Delling G, Mundy GR . Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Electron Microsc 1986: 1537–1554.

[37] Parfitt AM. Morphometry of bone resorption: introduction and overview. Bone, 1993, 14: 435-441

[38] Jevon M, Sabokbar A, Fujikawa Y et al Gender- and age-related differences in osteoclast formation from circulating precursors. J Endocrinol, 2002, 172: 673-681

[39] Michelsen J, Wallaschofski H, Friedrich N et al Reference intervals for serum concentrations of three bone turnover markers for men and women. Bone, 2013, 57: 399-404

[40] Morgan JL, Heer M, Hargens AR et al. Sex-specific responses of bone metabolism and renal stone risk during bed rest. Physiol Rep 2014; 2(8). pii: e12119.

[41] Minisola S, Dionisi S, Pacitti MT et al Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int, 2002, 13: 171-175

[42] Doumouchtsis KK, Kostakis AI, Doumouchtsis SK et al sRANKL/osteoprotegerin complex and biochemical markers in a cohort of male and female hemodialysis patients. J Endocrinol Invest, 2007, 30: 762-766

[43] Wang J, Stern PH. Sex-specific effects of estrogen and androgen on gene expression in human monocyte-derived osteoclasts. J Cell Biochem, 2011, 112: 3714-3721

[44] Everts V, de Vries TJ, Helfrich MH. Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions. Biochim Biophys Acta, 2009, 1792: 757-765

[45] Henriksen K, Bollerslev J, Everts V, Karsdal MA. Osteoclast activity and subtypes as a function of physiology and pathology--implications for future treatments of osteoporosis. Endocr Rev, 2011, 32: 31-63

[46] Everts V, Korper W, Docherty AJ, Beertsen W. Matrix metalloproteinase inhibitors block osteoclastic resorption of calvarial bone but not the resorption of long bone. Ann N Y Acad Sci, 1999, 878: 603-606

[47] Geblinger D, Geiger B, Addadi L. Surface-induced regulation of podosome organization and dynamics in cultured osteoclasts. Chembiochem, 2009, 10: 158-165

[48] Duong LT. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. Bonekey Rep, 2012, 1: 67